US 12,331,098 B2
SIRPalpha-41BBL fusion protein and methods of use thereof
Noam Shani, Zikhron-Yaakov (IL); Yosi Gozlan, Rehovot (IL); Michal Dranitzki Elhalel, Shoresh (IL); Edwin Bremer, Groningen (NL); and Ido Kaminsky, Ramat-Gan (IL)
Assigned to KAHR Medical Ltd., Modiln Makabim-ReUt (IL)
Filed by KAHR Medical Ltd., Modiln Makabim-ReUt (IL)
Filed on Dec. 13, 2023, as Appl. No. 18/537,886.
Application 17/400,179 is a division of application No. 16/473,631, granted, now 11,130,796, issued on Sep. 28, 2021, previously published as PCT/IL2018/050017, filed on Jan. 4, 2018.
Application 18/537,886 is a continuation of application No. 17/400,179, filed on Aug. 12, 2021, granted, now 11,897,937.
Claims priority of provisional application 62/442,469, filed on Jan. 5, 2017.
Prior Publication US 2024/0109952 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 19/00 (2006.01); A61K 38/17 (2006.01); A61K 40/10 (2025.01); A61K 40/42 (2025.01); A61K 47/65 (2017.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/70578 (2013.01) [A61K 40/10 (2025.01); A61K 40/42 (2025.01); A61K 40/4254 (2025.01); A61K 47/65 (2017.08); A61P 35/02 (2018.01); C07K 14/70596 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/2893 (2013.01); C12N 5/0638 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01)] 20 Claims
 
1. An article of manufacture comprising a packaging material comprising:
(i) a therapeutic agent for treating cancer selected from the group consisting of a chemotherapeutic agent, a radiotherapeutic agent, a cytotoxic agent and an antibody; and
(ii) a signal regulatory protein a (SIRPα)-4-1BB ligand (41BBL) fusion protein, wherein said fusion protein is characterized by a single amino acid linker between said SIRPα and said 41BBL and being in a form of a homotrimer.